Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients
Laurus Labs Limited
-(LAURUSLABS)
XNSE:LAURUSLABS, XBOM:LAURUSLABS
Laurus Labs Ltd Q4 FY24 Earnings Conference Call Insights
Key highlights from Laurus Labs Ltd (LAURUSLABS) Q4 FY24 Earnings Concall R&D Progress Advanced several pipeline projects across offerings and augmented technology/manufacturing
Laurus Labs Ltd Q4FY24; 29% fall in Profits
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients
Laurus Labs Ltd Q3FY24; 89% fall in Profits
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients
Laurus Labs Limited Q3 FY24 Earnings Conference Call Insights
Key highlights from Laurus Labs Limited (LAURUSLABS) Q3 FY24 Earnings Concall Business Performance Gross margins remained resilient at over 52% for several
Laurus Labs Ltd Q2FY24; 79% fall in Profits
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadershipposition in select Active Pharmaceutical Ingredients (APIs)
Laurus Labs Limited Q2 FY24 Earnings Conference Call Insights
Key highlights from Laurus Labs Limited (LAURUSLABS) Q2 FY24 Earnings Concall Q2 FY24 Results Revenue declined 22% year-on-year to INR1,224 crores.. EBITDA
Laurus Labs Ltd Q1FY24; 94% fall in Profits
Laurus Labs is principally engaged in offering a broad and integrated portfolio of Active Pharmaceuticals Ingredients (API) including intermediates, Generic Finished dosage
Laurus Labs Limited Q4 FY23 Earnings Conference Call Insights
https://youtu.be/5Vtl-XMN8qg Key highlights from Laurus Labs Limited (LAURUSLABS) Q4 FY23 Earnings Concall Management Update: [00:09:24]LAURUSLABS said it invested in expanding non-ARV formulation
Laurus Labs Limited (LAURUSLABS) Q4 FY23 Earnings Concall Transcript
Laurus Labs Limited (NSE:LAURUSLABS) Q4 FY23 Earnings Concall dated Apr. 27, 2023. Corporate Participants: Satyanarayana Chava -- Founder & Chief Executive Officer V V
Laurus Labs Limited Q4FY23 Earnings
To meet the demands of the international pharmaceutical industry, Laurus Labs primarily provides a comprehensive and integrated portfolio of Active Pharmaceutical Ingredients
Laurus Labs Q3FY23 net profit rises by 32 percent
Pharmaceutical and biotechnology company Laurus Labs reported 32% year-on-year (YoY) rise in profit after tax to INR 203 crore for the quarter
Laurus Labs Limited Q3 FY23 Earnings Conference Call Insights
Key highlights from Laurus Labs Limited (LAURUSLABS) Q3 FY23 Earnings Concall Management Update: [00:03:57] LAURUSLABS said its strong results were driven by
Laurus Labs Limited (LAURUSLABS) Q3 FY23 Earnings Concall Transcript
Laurus Labs Limited (NSE:LAURUSLABS) Q3 FY23 Earnings Concall dated Jan. 30, 2023. Corporate Participants: Satyanarayana Chava -- Founder & Chief Executive Officer V V
Laurus Labs Limited Q3 FY23; Consolidated Revenue Jumps By 50%
Laurus Labs Limited (NSE: LAURUSLABS) reported Revenue from Operations for Q3 FY23 of ₹1,544.82 Crore up from ₹1028.76 Crore year on year,
Laurus Labs Limited Q2 FY23 Earnings Conference Call Insights
https://youtu.be/ZaM0EH45MvA Key highlights from Laurus Labs Limited (LAURUSLABS) Q2 FY23 Earnings Concall Management Update: [00:10:45] LAURUSLABS said that on the R&D front,
Laurus Labs Limited (LAURUSLABS) Q2 FY23 Earnings Concall Transcript
Laurus Labs Limited (NSE:LAURUSLABS) Q2 FY23 Earnings Concall dated Oct. 21, 2022 Corporate Participants: Satyanarayana Chava -- Chief Executive Officer V.V. Ravi Kumar -- Chief Financial Officer Analysts:
Laurus Labs Limited Q1 FY23 Earnings Conference Call Insights
https://youtu.be/gMXrmnAGz9Y Key highlights from Laurus Labs Limited (LAURUSLABS) Q1 FY23 Earnings Concall Management Update: LAURUSLABS said it expects the US filing pace
Laurus Labs Limited Q4 FY22 Earnings Conference Call Insights
https://youtu.be/83rl6ffkU9c Key highlights from Laurus Labs Limited (LAURUSLABS) Q4 FY22 Earnings Concall Management Update: LAURUSLABS said that based on its healthy product
Laurus Labs Limited Q3 FY22 Earnings Conference Call Insights
https://www.youtube.com/watch?v=Q_K9qU7RXvI Key highlights from Laurus Labs Limited (LAURUSLABS) Q3 FY22 Earnings Concall Management Update: In 3Q, the company faced some interim challenges